About Blood-Based Exacta^™

Exacta^™ is a comprehensive, in-depth and integrative cellular and molecular tumour analysis that examines a large number of data points to identify actionable tumour vulnerabilities.

This multi-analyte, multi-coordinate investigation integrates genomic alterations in more than 400 genes with expression changes across 20,802 genes to identify actionable mutations and pathways driving cancer.

When Exacta^™ May Be Considered

• First-line therapy has failed.
• Cancer has relapsed.
• Cancer is high-grade or metastatic.
• The cancer is newly diagnosed or difficult to treat.
• There is no well-established standard of care.
• The risk of therapy failure is high.

Integrative Methodology

• Targeted genes: SNVs, CNVs, InDels, tumour mutational burden and germline variants.
• RNA: Expression pathways, gene expression and fusion/rearrangement analysis.
• Pharmacogenetics: Genotyping for drug-metabolising enzymes, toxicity and efficacy.
• Chemosensitivity: In-vitro cell-based testing of cytotoxic drugs.
• Immunocytochemistry: Analysis of therapy-relevant protein markers.

Therapy Insights

• Targeted therapy: Evaluates relevant biomarkers and concurrent molecular indications of resistance and sensitivity.
• Cytotoxic therapy: Combines genetic analysis with in-vitro chemosensitivity testing on live tumour cells.
• Immunotherapy: Analyses PD-L1, tumour mutational burden and microsatellite instability or germline MMR genes, depending on the sample.
• Drug tolerance: Analyses germline variants in drug-metabolising enzymes linked to toxicity and adverse drug reactions.
• Additional options: Explores molecular features in recurrent or high-grade cancers that have progressed despite prior therapy.

Blood-Based Parameters and Methods

• Cell-free DNA analysis of 411 genes, including rearrangements and amplifications.
• Blood-based tumour mutational burden.
• Exosomal gene expression analysis of more than 20,000 genes and KEGG pathways.
• Circulating Tumour Cell enumeration and therapy-relevant ICC markers.
• In-vitro chemosensitivity testing on circulating tumour-associated cells.
• Pharmacogenetics guidance and germline MMR and BRCA1/2 gene analysis.
• Relevant clinical trials.

A Multi-Layered View of the Tumour

Exacta^™ combines genomic alterations, gene-expression pathways, pharmacogenetics, therapy-relevant protein markers and functional chemosensitivity results in one investigation.

The analysis is intended to support personalised treatment strategies for solid-organ cancers, including difficult and unresponsive cases. Results should be interpreted by a qualified healthcare professional alongside all other clinical information.